105 related articles for article (PubMed ID: 11847536)
21. In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Itokazu N; Sugimoto T
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):25-9. PubMed ID: 10667833
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of population pharmacokinetic parameters in phenytoin dosage adjustment.
Yukawa E; Higuchi S; Aoyama T
Chem Pharm Bull (Tokyo); 1989 Dec; 37(12):3363-6. PubMed ID: 2632085
[TBL] [Abstract][Full Text] [Related]
23. Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development.
Ueshima S; Aiba T; Sato T; Matsunaga H; Kurosaki Y; Ohtsuka Y; Sendo T
Biol Pharm Bull; 2011; 34(1):108-13. PubMed ID: 21212527
[TBL] [Abstract][Full Text] [Related]
24. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
Chung S; Choi J; Hyun T; Rha Y; Bae C
J Korean Med Sci; 1997 Dec; 12(6):553-8. PubMed ID: 9443096
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.
Yu HY
Ther Drug Monit; 1984; 6(4):414-23. PubMed ID: 6440321
[TBL] [Abstract][Full Text] [Related]
26. Predicting serum lithium concentration using Bayesian method: a comparison with other methods.
Higuchi S; Fukuoka R; Aoyama T; Horioka M
J Pharmacobiodyn; 1988 Mar; 11(3):158-74. PubMed ID: 3411433
[TBL] [Abstract][Full Text] [Related]
27. Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia.
Doré M; San Juan AE; Frenette AJ; Williamson D
Pharmacotherapy; 2017 Aug; 37(8):900-907. PubMed ID: 28574586
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy.
Zhang ZB; Ji SM; Han Y; Zang LL; Wang YH; Lu W; Wang L; Wu Y
Eur J Clin Pharmacol; 2017 Apr; 73(4):445-453. PubMed ID: 28064355
[TBL] [Abstract][Full Text] [Related]
29. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication.
May T; Rambeck B
Ther Drug Monit; 1990 Mar; 12(2):124-8. PubMed ID: 2107607
[TBL] [Abstract][Full Text] [Related]
30. Comparison of methods for the prediction of phenytoin concentrations.
Vázquez Rodríguez A; Santos Buelga D; Alonso González AC; Garcćia Sánchez MJ; Domínguez-Gil Hurlé A
J Clin Pharm Ther; 1991 Feb; 16(1):55-62. PubMed ID: 2026669
[TBL] [Abstract][Full Text] [Related]
31. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
Dutta S; Faught E; Limdi NA
J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
[TBL] [Abstract][Full Text] [Related]
32. [The effect of antiepileptic drug therapy on antioxidant enzyme activity and serum lipid peroxidation in young patients with epilepsy].
Sołowiej E; Sobaniec W
Neurol Neurochir Pol; 2003; 37(5):991-1003. PubMed ID: 15174247
[TBL] [Abstract][Full Text] [Related]
33. Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study.
Zhang L; Liu M; Qin W; Shi D; Mao J; Li Z
Front Pharmacol; 2023; 14():1228641. PubMed ID: 37869748
[No Abstract] [Full Text] [Related]
34. Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy.
Jiang DC; Wang L
Acta Pharmacol Sin; 2004 Dec; 25(12):1576-83. PubMed ID: 15569400
[TBL] [Abstract][Full Text] [Related]
35. Performance of Bayesian feedback to forecast lidocaine serum concentration: evaluation of the prediction error and the prediction interval.
Vozeh S; Uematsu T; Hauf GF; Follath F
J Pharmacokinet Biopharm; 1985 Apr; 13(2):203-12. PubMed ID: 4057058
[TBL] [Abstract][Full Text] [Related]
36. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
May TW; Rambeck B; Nothbaum N
Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
[TBL] [Abstract][Full Text] [Related]
37. Binding parameters of valproic acid to serum protein in healthy adults at steady state.
Kodama Y; Koike Y; Kimoto H; Yasunaga F; Takeyama M; Teraoka I; Fujii I
Ther Drug Monit; 1992 Feb; 14(1):55-60. PubMed ID: 1546390
[TBL] [Abstract][Full Text] [Related]
38. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy.
Galimberti CA; Mazzucchelli I; Arbasino C; Canevini MP; Fattore C; Perucca E
Epilepsia; 2006 Sep; 47(9):1569-72. PubMed ID: 16981874
[TBL] [Abstract][Full Text] [Related]
39. The predictive performances of equations used to estimate unbound phenytoin concentrations in a medical ICU population and the impact of exogenous albumin administration.
Parikh L; MacLaren R
J Crit Care; 2018 Apr; 44():95-100. PubMed ID: 29078132
[TBL] [Abstract][Full Text] [Related]
40. Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy.
Dwivedi R; Gupta YK; Singh M; Joshi R; Tiwari P; Kaleekal T; Tripathi M
Seizure; 2015 Feb; 25():187-90. PubMed ID: 25455060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
